Skip to main content

Remote Job Finders (RJF)

Amgen Ends Autoimmune Alliance With Kyowa Kirin Amid Safety, Efficacy Questions

A Phase III readout in September 2024 for rocatinlimab, on which Amgen and Kyowa Kirin were collaborating in atopic dermatitis, appeared underwhelming to analysts, with Jefferies noting that the data “came in at the lower end of efficacy and expectations.”

Eikon, Veradermics, Announce IPO Targets as Cautious Optimism Propels Biotech Market

Cancer-focused Eikon Therapeutics is seeking $273.5 million in its bid to trade on the Nasdaq, while hair growth specialist Veradermics is looking for $181.1 million in its foray onto the New York Stock Exchange.
Scroll to top